Immunovant (IMVT) is back in focus after reporting a wider than expected quarterly loss tied to IMVT-1402 development and batoclimab discontinuation costs, along with updates on its Graves' Disease and CIDP programs.

Against that backdrop, Immunovant’s share price has risen strongly, with a 90 day share price return of 53.79% and a 1 year total shareholder return of 123.67%, signaling firm momentum as investors weigh its IMVT-1402 and CIDP updates.

If Immunovant’s recent move has your attention, this could be a good moment to scout other healthcare opportunities using our screener of 40 healthcare AI stocks

Given Immunovant’s strong recent returns, a Zacks Rank #3 (Hold), and shares trading below the average analyst price target, the key question now is simple: is there still upside on the table, or is the market already pricing in future growth?

Most Popular Narrative: 14.1% Undervalued

Immunovant’s most followed narrative points to a fair value of $41.13 versus the last close at $35.34, putting the current analyst assumptions in sharp focus.

The fully enrolled D2T RA study for IMVT-1402, upsized to 170 patients, reflects strong physician and patient engagement that could support broader adoption in difficult to treat autoimmune populations over time, which would be most visible in revenue growth if late stage data are supportive.

Want to understand why this valuation leans on long dated revenue, rising margins and a premium future earnings multiple, all before profitability arrives? The narrative breaks down how those moving parts fit together and which assumptions really carry the weight in getting to that fair value.

Result: Fair Value of $41.13 (UNDERVALUED)

However, the Immunovant story still hinges on successful IMVT-1402 trials and future financing choices, and clinical setbacks or additional dilution could quickly challenge this undervaluation case.

Next Steps

With the Immunovant story finely balanced between opportunity and risk, it makes sense to move quickly, review the details, and test your own thesis against the 5 important warning signs

Looking for more investment ideas beyond Immunovant?

Do not stop with Immunovant alone. Broaden your watchlist and give yourself more options by checking other stocks that fit different risk and return profiles.

• Target higher income potential by reviewing companies in the 8 dividend fortresses that may suit an income focused portfolio.
• Spot possible mispriced opportunities early by scanning the screener containing 19 high quality undiscovered gems before they gain wider attention.
• Prioritize capital preservation by concentrating on companies highlighted in the 66 resilient stocks with low risk scores that score well on stability measures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.